Table 2: COVID-19 status by demographic, clinical, and treatment characteristics of patients with IBD .
| Variable |
Overall
2159 (100%) |
Without COVID
2075 (96.11%) |
With COVID
84 (3.89%) |
P value |
| Disease type, n (%) | ||||
| Crohn’s disease | 546 (25.2) | 522 (25.1) | 24 (28.57) | 0.630 |
| IC | 23 (1.1) | 23 (1.1) | 0 (0.00) | |
| Ulcerative colitis | 1590 (73.6) | 1530 (73.7) | 60 (71.43) | |
| Age (y), n (%) | ||||
| 0-9 | 46 (2.1) | 45 (2.1) | 1 (1.1) | 0.304 |
| 10-19 | 318 (14.7) | 307 (14.8) | 11 (13.1) | |
| 20-29 | 702 (32.5) | 678 (32.7) | 24 (28.5) | |
| 30-39 | 474 (21.9) | 448 (21.6) | 26 (30.9) | |
| 40-49 | 337 (15.6) | 327 (15.7) | 10 (11.9) | |
| 50-59 | 198 (9.1) | 189 (9.1) | 9 (10.7) | |
| 60-69 | 63 (2.9) | 62 (2.9) | 1 (1.1) | |
| ≥70 | 18 (0.8) | 16( 0.77) | 2 (2.38) | |
| Sex, n (%) | ||||
| Male | 1004 (46.6) | 969 (46.8) | 35 (41.6) | 0.373 |
| Female | 1147 (53.3) | 1098 (53.1) | 49 (58.3) | |
| Comorbidity, n (%) | ||||
| Hypertension | 162 (7.5) | 151 (7.2) | 11 (13.1) | 0.056 |
| Coronary heart disease | 85 (3.9) | 80 (3.8) | 5 (5.9) | 0.380 |
| Diabetes | 103 (4.7) | 96 (4.6) | 7 (8.3) | 0.117 |
| Asthma | 45 (2.0) | 43 (2.0) | 2 (2.3) | 0.694 |
| Cancer | 11 (0.5) | 11 (0.5) | 0 (0.0) | 1.000 |
| History of stroke | 0 (0) | 0 (0) | 0 (0) | - |
| COPD | 0 (0) | 0 (0) | 0 (0) | - |
| Chronic renal disease | 52 (2.4) | 48 (2.3) | 4 (4.7) | 0.141 |
| Chronic liver disease | 130 (6.0) | 122 (5.8) | 8 (9.5) | 0.161 |
| Current smoker | 96 (4.4) | 91 (4.3) | 5 (5.9) | 0.420 |
| Tobacco | 51 (2.3) | 50 (2.4) | 1 (1.1) | 0.721 |
| Other | 102 (4.7) | 96 (4.6) | 6 (7.1) | 0.287 |
| Number of comorbidities, n (%) | ||||
| 0 | 1523 (70.5) | 1473 (70.9) | 50 (59.5) | 0.015* |
| 1 | 475 (22.0) | 453 (21.8) | 22 (26.1) | |
| 2 | 110 (5.0) | 104 (5.0) | 6 (7.1) | |
| ≥3 | 51 (2.3) | 45 (2.1) | 6 (7.1) | |
| IBD disease activity, n (%) | ||||
| Remission | 1386 (64.3) | 1341 (64.7) | 45 (53.5) | 0.026* |
| Mild | 426 (19.7) | 410 (19.8) | 16 (19.0) | |
| Moderate | 230 (10.6) | 216 (10.4) | 14 (16.6) | |
| Severe | 113 (5.2) | 104 (5.0) | 9 (10.7) | |
| Concomitant therapy for IBD, n (%) | ||||
| 5-ASA | 1556 (72.1) | 1497 (72.1) | 59 (70.2) | 0.710 |
| Corticosteroids | 128 (5.9) | 115 (5.5) | 13 (15.4) | 0.001* |
| Thiopurines, 6 MP, MTX | 695 (32.1) | 667 (32.1) | 28 (33.3) | 0.813 |
| Anti-TNF without Thiopurines, 6 MP, MTX | 306 (14.1) | 286 (13.7) | 20 (23.8) | 0.016* |
| Anti-TNF with Thiopurines, 6 MP, MTX | 191 (8.8) | 180 (8.6) | 11 (13.1) | 0.168 |
| JAK inhibitor | 27 (1.2) | 27 (1.3) | 0 (0.0) | 0.623 |
Abbreviations: IC, Indeterminate colitis; COPD, Chronic Obstructive Pulmonary Disease; 5-ASA, 5-Aminosalicylic Acid; AZA, Azathioprine; MTX, Methotrexate; JAK, Janus Kinase.
*Statistically significant